Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
Status:
Completed
Trial end date:
2019-01-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the immunogenicity of Peg-filgrastim versus Neulasta®
as an adjunct to chemotherapy in patients with breast cancer